Treatment of the feline atopic syndrome – a systematic review

Ralf S. Mueller*, Tim Nuttall†, Christine Prost‡, Bianka Schulz* and Petra Bizikova§

*Small Animal Clinic, Centre for Clinical Veterinary Medicine, LMU Munich, Munich, Germany
†Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Campus, Roslin, EH25 9RG, UK
‡Orange, 393 Route du parc 84100, Paris, France
§Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA

Correspondence: Ralf S. Mueller, Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstr 13, 80539 Munich, Germany.
E-mail: r.mueller@lmu.de

Background – Feline allergic skin disease and asthma occur regularly in small animal practice.

Objectives – To provide evidence-based recommendations for small animal practitioners on the treatment of feline atopic syndrome (FAS).

Methods and materials – The authors reviewed the literature available before February 2020, prepared a detailed evidence-based literature review and made recommendations based on the evaluated evidence.

Results – Sixty-six papers and abstracts were identified describing treatment interventions for FAS and evaluated to establish treatment recommendations. For many treatment options, the papers were retrospective, open studies or case reports.

Conclusion and clinical relevance – In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergen-specific immunotherapy in feline atopic skin syndrome. Evidence pointed to low-to-moderate efficacy for antihistamines, fatty acids and palmitoyl ethanolamide. In feline asthma, there was good evidence for the efficacy of oral and inhaled glucocorticoids, and limited evidence of moderate efficacy for allergen-specific immunotherapy. Evidence supported low-to-moderate efficacy of mesenchymal stem cells, inhaled lidocaine and oclacitinib as treatments for feline asthma. For almost all therapeutic options (with the exception of glucocorticoids and ciclosporin), more randomised controlled trials are needed.

Introduction

Feline atopic syndrome (FAS) is the newly-proposed terminology encompassing allergic diseases of the skin, gastrointestinal and respiratory tract in the cat. Feline atopic skin syndrome (FASS) describes allergic skin disease associated with environmental allergies.1–3 Allergic dermatitis in the cat presents with multiple cutaneous reaction patterns that all may be caused by environmental, food and/or insect allergens, as well as other diseases. Those reaction patterns include miliary dermatitis, self-limited alopecia/hypotrichosis, the eosinophilic granuloma complex (eosinophilic granuloma, eosinophilic plaque, indolent ulcer) and/or excoriations-ulcers on the head and neck.3 Consequently, the treatment of these reaction patterns will depend on their aetiology, and other causes such as food allergy or flea bite hypersensitivity must be ruled out before diagnosing FASS. Feline asthma is a common lower airway inflammatory condition in cats with significant morbidity and occasional mortality. From a clinical and pathogenetic point of view, feline asthma is remarkably similar to the human disease. As in humans, affected cats exhibit a spontaneous and natural hyper-reactivity of the airways resulting in a reversible bronchoconstriction, airway inflammation and chronic remodelling.4 Intradermal and serum testing for allergen-specific immunoglobulin (Ig)E is not suitable for the diagnosis of FAS. Similar to dogs, the FASS is diagnosed based on the history, clinical signs and exclusion of differential diagnoses appropriate to each case.5 Over the last decades, different treatments have been reported for FAS variants, yet to the best of the authors’ knowledge, a systematic review of all available therapeutic and diagnostic approaches is lacking.

Accepted 28 October 2020

Source of Funding: This study was selffunded.

Conflicts of Interest: Within the last five years, Ralf Mueller has been a consultant, lecturer, or has received financial support for studies from Artuvet, Bayer Animal Health, Ceva Animal Health, Elanco Animal Health, Greer Laboratories, Heska Laboratories, Hill’s, Royal Canin, MSD Animal Health, Neutnmune, Synlab, Virbac Animal Health and Zoetics. Tim Nuttall has received fees and/or has arrangements or affiliations within the last five years with Avacta Animal Health, Bova UK, Ceva Animal Health, Elanco Animal Health, ICF srl, Norbrook Laboratories, Virbac Animal Health and Zoetics. Christine Prost is an employee of Sanofi Pasteur. Bianka Schulz has been a consultant, lecturer or has received financial support for studies from Boehringer Ingelheim, Ceva Animal Health, Laboklin, Merial, Idexx and Zoetics. Petra Bizikova has not report any conflicts of interest.

ICADA cannot be held responsible for errors or any consequences arising from the use of information contained in this article. Readers need to bear this in mind and be aware of the prescribing laws pertaining to their own countries.

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology. 32, 43–e8.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
preventive interventions has not been published. The aim of this review was therefore to summarise and review the published evidence for the various treatment options for the cutaneous and respiratory components of FAS. It was not within the remit of this paper to discuss the aetiology, pathogenesis and diagnosis of these diseases. These subjects are reviewed in other papers in this series and readers are directed to them for more information.1–3

Methods and materials

In order to evaluate the efficacy and safety of treatments for the two main FAS manifestations (FASS and asthma), online bibliographic databases (PUBMED and WEB OF SCIENCE) and scientific meeting proceedings were searched for relevant published studies or abstracts of sufficient detail for analysis. The bibliographies of identified studies and of main veterinary dermatology textbooks were further evaluated. Studies were analysed and their value determined based on the quality of their evidence (QOE). They were summarised and, based on the available data, a given treatment’s efficacy was determined and its reported adverse effects listed. Thereafter a recommendation about each treatment option was given, with the strength of recommendation (SOR) based on the QOE (Table 1).

Data evaluation and strength of recommendations were modelled based on the quality of their evidence (QOE). They were summarised and, based on the available data, a given treatment’s efficacy was determined and its reported adverse effects listed. Thereafter a recommendation about each treatment option was given, with the strength of recommendation (SOR) based on the QOE (Table 1).

Results

We found a total of 72 papers and abstracts describing treatment interventions for FAS. These included 58 clinical trials and eight case reports evaluating efficacy of treatments,9–16 five safety and pharmacokinetic studies in healthy cats,17–21 and one retrospective safety study (without reporting efficacy).22 Of the 55 clinical trials, six were available only as abstracts23–28 and 49 had been published in peer-reviewed journals. There were 48 prospective and 10 retrospective studies,23–31 while 29 were randomised, controlled23–49 and often blinded.26,42,60–79 These studies included clinical trials on allergen avoidance, allergen-specific immunotherapy (ASIT), topical, inhaled and systemic glucocorticoids, ciclosporin, oclacitinib, bronchodilators, H1-receptor (H1R) antihistamines, essential fatty acids (EFA) and palmytoylethanolamide, antibiotics, inhaled lidocaine and mesenchymal stem cells. Thirty-three of the reports described in the latter report. One larger study was based on previous practice guidelines for human6,7 and canine atopic dermatitis (cAD).8

Analysis of evidence

In one retrospective study of 29 asthmatic cats,35 and one prospective study on 20 asthmatic cats,47 avoidance of allergens was reported for individual cases. We could not find any such evidence for FASS.

Recommendations

Although allergen avoidance is common sense and should be effective (QOE 3; SOR C), it is often unfeasible in cats sensitised to environmental allergens. There is only limited evidence for the benefit of allergen avoidance in asthmatic cats,35,47 and no such information exists for FASS.

ASIT

Analysis of evidence

Eleven reports evaluated ASIT in a total of 197 cats with FASS.12,13,15,16,23,25,28–32 Five retrospective studies specifically evaluated ASIT in 70 cats with different reaction patterns of FASS,23,25,30,32 Seventeen cats had miliary dermatitis, 21 had noninflammatory alopecia, 18 had eosinophilic lesions,16,25,30,32 and in one study the clinical signs were not detailed.23 Two of these reports were abstracts in proceedings from World Congresses of Veterinary Dermatology and thus not sufficiently detailed.23,25 Likewise, one prospective open study evaluating sublingual ASIT was a conference abstract.28 One report described the response to ASIT in three littermates with atopic skin disease,12 one case series described four cats with miliary dermatitis and eosinophilic granuloma,16 and another focused on rush immunotherapy (RIT) in four atopic cats,13 although treatment outcomes were not described in the latter report. One larger study was based on a questionnaire sent out by a laboratory after serum testing for allergen-specific IgE and subsequent orders for ASIT in 81 cats, six of which had lower respiratory tract disease.29 The last study evaluated 45 cats with FASS, 23 of which underwent AIT.31 Definitions of a good, moderate, partial or no response varied and often were unclear. In one study, an excellent response was described as complete remission of the patient with no concurrent medication and was seen in 26% of the

Table 1. Strength of recommendation taxonomy (SORT)

<table>
<thead>
<tr>
<th>Strength of recommendation (SOR)</th>
<th>Quality of evidence (QOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1</td>
</tr>
<tr>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>C</td>
<td>3</td>
</tr>
<tr>
<td>Based on consistent and good quality patient-orientated evidence</td>
<td>Good quality, patient-orientated</td>
</tr>
<tr>
<td>Based on inconsistent or limited quality patient-orientated evidence</td>
<td>Limited quality, patient-orientated</td>
</tr>
<tr>
<td>Based on consensus, usual practice, opinion, disease-orientated evidence or case series</td>
<td>Other evidence (usual practice, opinion, or disease-orientated evidence)</td>
</tr>
</tbody>
</table>

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology. 32, 43–e8.
In the study using a survey sent out to veterinarians treating cats with ASIT after serum testing for allergen-specific IgE, lesional scores were assigned and the percentage of improvement calculated. In another study, concurrent medications were not discussed; in many reports concurrent medications were mentioned and details not given.

Five studies evaluated cats with respiratory disease/asthma. In an older retrospective study, veterinarians submitting feline serum specimens for allergen-specific IgE testing were asked to complete a follow-up questionnaire, six cats with respiratory clinical signs undergoing ASIT were included. One study focussed on ASIT as treatment for 12 asthmatic cats showing sensitization to aeroallergens based on intradermal testing. Three studies were performed in an experimental model of feline asthma in which cats were sensitised to Bermuda grass and house dust mites. In the first randomised controlled trial (RCT), intranasal or subcutaneous RIT were compared. In a second study using the same model, cats received RIT with an allergen that they were not sensitised to or with only one of the two allergens they were sensitised to. The third study evaluated the influence of oral and inhaled glucocorticoids on the outcome of RIT. In one conference abstract, a cat with cutaneous and respiratory signs was treated with ASIT using a recombinant Der f 2-based vaccine.

### Table 2. Responses to allergen immunotherapy in 194 cats with naturally occurring feline atopic skin syndrome (FASS)

<table>
<thead>
<tr>
<th>Type of Allergen (number of cats evaluated)</th>
<th>Dose</th>
<th>Responses</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Der f 2-pullulan-based vaccine (n = 1)</td>
<td>Not reported; allergens administered weekly for six months</td>
<td>Good-excellent</td>
<td>Martin et al. 201915 Case report</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical remission with cessation of topical glucocorticoids and oral oclacitinib</td>
<td></td>
</tr>
<tr>
<td>Not reported (n = 19)</td>
<td>Not reported; allergens administered for 6 months</td>
<td>SCORFAD reduced from 22 to 5.7, pruritus score from 7.9 to 3.6</td>
<td>Foj et al. 201928 Abstract of case series</td>
</tr>
<tr>
<td>Not reported (n = 23)</td>
<td>Good in 13, Partial in 6, Poor in 4</td>
<td></td>
<td>Ravens et al. 201441 ReSt</td>
</tr>
<tr>
<td>Aqueous allergens (n = 4)</td>
<td>11,000-22,000 PNU every 7-35 days administered for 8-24 months</td>
<td>Good in 2</td>
<td>Schnabl et al. 200616 Case series</td>
</tr>
<tr>
<td>Aqueous allergens (n = 3)</td>
<td>20,000 PNU every three weeks</td>
<td>1 good (no other medications, but still mild clinical signs), 5 excellent (remission)</td>
<td>Bettenay 199823 ReSt</td>
</tr>
<tr>
<td></td>
<td>Not reported; allergens administered every 10 days</td>
<td>Poor in 2</td>
<td>Morello 200112 Case report</td>
</tr>
<tr>
<td></td>
<td>10,000 PNU every four weeks</td>
<td>Good in 10 cats, Poor in 5 cats</td>
<td>Reedy 198232 Case series</td>
</tr>
<tr>
<td>Phosphate Ca-bound allergens (n = 22)</td>
<td>Not reported</td>
<td>16 in remission with very mild pruritus and no medication</td>
<td>Prost 199225 Case series</td>
</tr>
<tr>
<td></td>
<td>9 cats good response (&gt;50% improvement with no other drugs)</td>
<td>5 moderate improvement (approximately 50% improvement with occasional other drugs)</td>
<td>McDougall 198630 Case series</td>
</tr>
<tr>
<td>Aqueous allergens (n = 13)</td>
<td>1 mL every four weeks</td>
<td>Good in 10 cats</td>
<td>Reedy 198232 Case series</td>
</tr>
<tr>
<td></td>
<td>10 cats 100% improvement, 39 cats 75-99%</td>
<td>Poor in 5 cats</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 cats 50-75%, 6 ≤ 50%</td>
<td>2 still on regular glucocorticoids</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 cats slight improvement, 6 cats no change or deterioration</td>
<td>1 poor response</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not reported</td>
<td>9 cats good response (&gt;50% improvement with no other drugs)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 mL every four weeks</td>
<td>Good in 10 cats</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100% improvement, 50% satisfaction</td>
<td>Poor in 5 cats</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50% improvement, 25% satisfaction</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25% improvement, 10% satisfaction</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>Mean outcomes (n = 15)</td>
<td>60%</td>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

QOE quality of evidence, RCT randomised controlled trial, ReS retrospective study, SCORFAD Scoring Feline Allergic Dermatitis.
Analysis of efficacy
The results of ASIT for FASS were reported in 210 cats (Table 2). The reported efficacy was between 45 and 75%, similar to what is reported for dogs. One of the studies did not evaluate treatment outcome, and looked only at the safety of RIT in four cats with FASS. Results of ASIT in 80 cats with asthma are listed in Table 3. In one study a complete remission of clinical signs was observed in eight of 12 cats with naturally occurring asthma (67%) in which symptomatic therapy with glucocorticoids could be discontinued on ASIT. Four cats still required pharmacotherapy, including inhaled corticosteroids and bronchodilators. In a retrospective study, veterinarians treating 12 cats with suspected feline asthma reported a good response via questionnaire.

Three studies evaluated ASIT in cats with experimentally induced asthma. In the first RCT, intranasal or subcutaneous RIT improved clinical signs and dampened eosinophilic inflammation of the airways. However, intranasal RIT had fewer adverse effects and a decreased interleukin (IL)-4/interferon-gamma ratio in the bronchoalveolar lavage fluid (BALF). In the second study, airway eosinophilia decreased and the percentage of regulatory T cells and IL-10-producing cells increased in cats treated with RIT compared to controls independent of their sensitisation status and content of the allergen extract, indicating nonspecific effects. However, only matched allergens could potentially induce an immunological cure. In the same model of feline asthma, cats given oral prednisolone at 10 mg once daily over the first six months of ASIT showed an increased percentage of eosinophils in the BALF after nine months of ASIT by contrast with inhaled fluticasone at 220 mcg twice daily.

Adverse effects
Adverse effects were not mentioned in ten reports. After RIT, two of four cats showed increased pruritus and in two of four a dermal alopecic nodule developed one week after initiation of therapy.

Recommendations
ASIT seems to be an efficacious therapy for FASS (QOE 2; SOR B). However, some studies were presented only as abstracts with very limited information, none of the studies were controlled or randomised, and all were characterised by unclear outcome measures, making final assessment difficult. By contrast, there is evidence of moderate-to-good efficacy of ASIT in naturally occurring feline asthma (QOE 2; SOR B) and moderate efficacy of RIT in cats with experimental asthma (QOE 1; SOR A). Adverse effects seem to be rare (QOE 1; SOR A). More studies on ASIT in cats are needed urgently.

Systemic glucocorticoids
Analysis of evidence
Three prospective double-blinded RCTs evaluated systemic glucocorticoid treatment in cats with FASS. One prospective study looked at the diabetogenic potential of prednisolone and dexamethasone in healthy cats. The three clinical trials included 63 cats: 11 treated with prednisolone, 36 with methylprednisolone and 16 with triamcinolone. The treatment regimens used dosages of 1 mg/kg once daily of prednisolone, 0.77 mg/kg twice daily (20 cats) to 1.4 mg/kg once daily (16 cats) of methylprednisolone, and 0.18 mg/kg once daily of triamcinolone acetonide for 28 days to 84 days. The latter study used daily treatment for ≤14 days to achieve remission and then tapered treatment resulting in final alternate day dosages of 0.54 mg/kg methylprednisolone and 0.08 mg/kg triamcinolone. Pruritus was assessed using a 0–10 Visual Analog Scale (VAS) in two studies and a 0–5 Linear Analog Scale in one. Lesion scores were assessed using the Canine Atopic Dermatitis Extent and Severity Index, 2nd iteration (CADESI-02), a Feline Dermatitis and the American College of Veterinary Dermatology., 32, 43–e8.

Table 3. Responses to allergen immunotherapy in 82 cats with naturally occurring and experimental asthma

<table>
<thead>
<tr>
<th>Type of Allergen (number of cats evaluated)</th>
<th>Dosage</th>
<th>Responses</th>
<th>References Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alum-precipitated allergens (n = 12, EX)</td>
<td>200 mcg weekly Bermuda grass allergen SC or intranasally for six months</td>
<td>Respiratory scores and eosinophil % in BALF decreased,</td>
<td>Lee-Fowler et al. 2009 RCT</td>
<td>1</td>
</tr>
<tr>
<td>Alum-precipitated allergens (n = 18, EX)</td>
<td>200 mcg weekly Bermuda grass allergen SC for nine months, additional oral or inhaled glucocorticoids for the first six months (n = 6 each)</td>
<td>Decrease in eosinophil % and IL-5 in BALF</td>
<td>Chang et al. 2013 RCT</td>
<td>1</td>
</tr>
<tr>
<td>Alum-precipitated allergens (n = 38, EX)</td>
<td>200 mcg/week for six months</td>
<td>Decrease in eosinophil % and lymphocyte proliferation stimulation index, increase in CD4+ CD25+ FoxP3+ T cells</td>
<td>Reinero et al. 2012 RCT</td>
<td>1</td>
</tr>
<tr>
<td>Allergens adsorbed on Calcium phosphate gel (n = 12)</td>
<td>1 mL every 28 days for six to nine months</td>
<td>Remission in 8/12 cats</td>
<td>Prost 2008 Case series</td>
<td>2</td>
</tr>
<tr>
<td>Not reported (n = 4)</td>
<td>Not reported</td>
<td>Mean percentage clinical improvement 89.5%</td>
<td>Halliwel 1997 ReSt</td>
<td>3</td>
</tr>
</tbody>
</table>

BALF bronchoalveolar lavage fluid, EX experimental asthma, NO naturally occurring asthma, QOE quality of evidence, ReSt retrospective study, RCT randomised controlled trial, SC subcutaneously.
Erythema, Excoration and Alopecia score (FEEAS; a modified CADESI-03 score omitting lichenification),\(^60\) and a Scoring Feline Allergic Dermatitis (SCORFAD) scale.\(^62\) Only the SCORFAD scale had been validated for pruritic and eosinophilic skin lesions in cats.\(^84\),\(^85\) One study\(^62\) included a validated Quality of Life (QoL) score.\(^86\) The cats presented with pruritus and a variety of the recognised reaction patterns associated with FASS. Most cats presented with more than one type of lesion. The seasonality of the clinical signs was not recorded.

One cross-over RCT compared oral prednisolone at 10 mg/day with inhaled flunisolide at 250 µg twice daily in six cats with feline asthma experimentally sensitised to Bermuda grass.\(^66\) Another cross-over RCT treated six cats sensitised to *A. suum* with either oral prednisolone at 1 mg/kg twice daily, 500 mcg of inhaled fluticasone propionate twice daily, or a combination of inhaled fluticasone propionate and salbutamol at 500 mcg and 50 mcg, respectively, for four consecutive days.\(^71\) A study with 14 client-owned cats with lower airway disease assessed airway function before and after prednisolone therapy.\(^48\)

**Analysis of efficacy**

Treatment outcome data were available for 63 cases with FASS (see Table 4). Cats that responded to treatment were reported to do so within 7–14 days. There was no association between the responses to treatment and the type of lesions.

Although prednisolone decreased allergen-specific IgE and the percentage of eosinophils in the BALF of cats experimentally sensitised to Bermuda grass, it did not improve airway hyper-reactivity in response to methacholine.\(^66\) In the *A. suum*-sensitised cats there were no significant differences in respiratory rate or Penh Jan estimate of airflow limitation measured by conventional barometric whole body plethysmography (BWBP)\(^1\) between the treatment groups.\(^71\) Allergen-induced airway hyperResponsiveness was significantly inhibited by the oral prednisolone, inhaled fluticasone propionate and inhaled fluticasone propionate/salbutamol. The mean BALF eosinophil percentage was lower after oral and inhaled corticosteroid treatment and these changes were significant for groups receiving prednisolone and the combination of inhaled fluticasone propionate/salbutamol,\(^71\) although the dose of inhaled fluticasone was fairly high. In the study with client-owned cats with lower airway disease, a significantly decreased peak to mid-expiratory flow and no significant changes in other BWBP parameters were noted after at least three weeks of therapy with prednisolone at 1.2–2 mg/kg once daily.\(^48\)

**Adverse effects**

Clinical adverse effects were uncommon, with one case each of vomiting and lethargy among the 20 cats treated with methylprednisolone.\(^62\) Clinico pathological abnormalities included increased liver enzymes in one of 16 triamcinolone- and eight of 36 methylprednisolone-treated cats.\(^50\),\(^62\) Hyperglycaemia was seen in four, altered haematological parameters in four, and glycosuria in one of the 36 methylprednisolone-treated cats. Mean albumin and fructosamine levels significantly increased in triamcinolone- (n = 16) and methylprednisolone-treated cats (n = 16) and remained within the reference ranges.\(^60\) Amylase was elevated above the reference range in 10 of 15 triamcinolone- and two of 14 methylprednisolone-treated cats at the end of the induction phase, and returned to normal during the every other day maintenance phase.\(^60\) The safety study evaluated 14 cats treated with either 4.4 mg/kg once daily of prednisolone or 0.55 mg/kg once daily of dexamethasone for 56 days.\(^56\) Dexamethasone treatment resulted in significantly increased fructosamine concentration, decreased insulin sensitivity and secretion, and increased glycosuria, although the cats did not become hyperglycaemic at any point. No adverse effects were mentioned in most of the studies evaluating asthmatic cats.\(^48\),\(^66\),\(^71\) One study evaluated long-term effects of glucocorticoids in asthmatic cats and found adverse effects such as polyuria and polydipsia, diabetes mellitus and fungal infection in four of 34 cats.\(^27\) A study evaluating long-term safety (at least three years) of methylprednisolone in 25 cats detected an increase of

### Table 4. Responses to systemic glucocorticoid treatment in 63 cats with feline atopic skin syndrome (FASS)

<table>
<thead>
<tr>
<th>Glucocorticoid(^1) (number of cats evaluated)</th>
<th>Dosage</th>
<th>Response to treatment(^2)</th>
<th>References Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone (n = 16, not all cats had an elimination diet)</td>
<td>1.4 mg/kg once daily for over six weeks</td>
<td>95% decrease(^4)</td>
<td>Ganz 2012(^60) RCT</td>
<td>1</td>
</tr>
<tr>
<td>Methylprednisolone (n = 20)</td>
<td>0.77 mg/kg twice daily for 28 days</td>
<td>67% decrease(^3)</td>
<td>Noli 2019(^63) RCT</td>
<td>1</td>
</tr>
<tr>
<td>Triamcinolone (n = 16, not all cats had an elimination diet)</td>
<td>0.18 mg/kg once daily for over six weeks</td>
<td>95% decrease(^3)</td>
<td>Ganz 2012(^60) RCT</td>
<td>1</td>
</tr>
<tr>
<td>Prednisolone (n = 11)</td>
<td>1 mg/kg once daily for 28 days</td>
<td>5/11 improved 6/11 worse</td>
<td>Wisselink 2009(^64) RCT</td>
<td>2</td>
</tr>
</tbody>
</table>

\(1\) See text for the definitions of the responses to treatment.

\(2\) See text for the definitions of the responses to treatment.

\(3\) Mean improvement ± standard deviation.

\(4\) 13 of 16 cats achieved remission.

\(5\) Two of three cats that failed to achieve remission responded to higher doses of glucocorticoid.

\(6\) Three of 20 cats worsened.

\(7\) 14 of 16 cats achieved remission.

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology, 32, 43–e8. 47
triglycerides, amylase and monocytes, yet changes remained within the reference interval.\textsuperscript{87}

**Recommendations**

Systemic glucocorticoids are rapid and effective in most cats with FASS (QOE 1; SOR A). Treatment with 1.4–1.5 mg/kg once daily of methylprednisolone-induced remission in 33 of 36 cats within 14 days. The similar response to 0.18 mg/kg once daily of triamcinolone acetoniode suggests that this drug has seven-fold greater potency than methylprednisolone. It is therefore likely that equipotent doses of other glucocorticoids will be likewise effective (QOE 3; SOR C). By contrast, 1 mg/kg once daily of prednisolone (approximately 50% of the above dosages) was much less effective. Once in remission, treatment can be tapered to the lowest and least frequent dosage that maintains remission (QOE 1; SOR A). On average, this equated to 20–25% of the starting dosage. Once-daily treatment is advised (QOE 1; SOR A). There was no difference in the efficacy of methylprednisolone at 0.77 mg/kg twice daily and 1.4 mg/kg once daily. One study noted that twice-daily dosing reduced QoL scores.\textsuperscript{62} Systemic glucocorticoids at these doses were well-tolerated, although all of the studies were short-term. However, altered haematology, serum biochemistry and urinalysis parameters were frequent (particularly markers of glucose metabolism). Regular monitoring of cats on a long-term treatment with systemic glucocorticoids is therefore warranted, especially with more diabetogenic drugs such as dexamethasone (QOE 1, SOR A).

In feline asthma, there is good evidence for clinical efficacy of oral glucocorticoids (QOE 1; SOR A) although most of this evidence is based on experimentally sensitised cats.

**Topical and inhaled glucocorticoids**

**Analysis of evidence**

There was one prospective open and uncontrolled clinical trial of topical 0.0584% hydrocortisone aceponate (HCA, Cortavance, Virbac; Carros, France) in 10 cats with perennial pruritus and lesions consistent with FASS.\textsuperscript{43} The cats were treated with two sprays per 10 x 10 cm area of affected skin from 10 am away daily for 28 days, followed by every other day dosing up to Day (D).\textsuperscript{43} The outcome measures included a pVAS,\textsuperscript{82} a validated Feline Dermatitis Extent and Severity Index lesion score (FeDESI),\textsuperscript{84} and a five point categorical score for efficacy, tolerance and ease-of-administration.

Four studies evaluated the use of inhaled glucocorticoids in an experimental model of feline asthma.\textsuperscript{65,66,68,71} In one study, inhaled flunisolide at 250 \( \mu \)g twice daily was compared with oral prednisolone at 10 mg once daily in six cats.\textsuperscript{66} In the second blinded cross-over RCT the effect of three different dosages of inhaled fluticasone propionate delivered by a metered-dose inhaler was investigated in six cats with experimentally induced allergic airway inflammation.\textsuperscript{68} A third cross-over RCT treated six cats sensitised to \( A. \ suum \) with either prednisolone (1 mg/kg twice daily), inhaled fluticasone propionate (500 mcg twice daily), or a combination of inhaled fluticasone propionate and salbutamol (500 mcg/50 mcg twice daily) for four consecutive days.\textsuperscript{71} In another study, sensitised cats underwent RIT and for the first six months concurrently received either oral prednisolone at 10 mg/kg/day/cat or 220 mcg twice-daily inhaled fluticasone/cat.\textsuperscript{66} One study investigated the effects of 400 mcg of inhaled budesonide twice daily on 37 cats with naturally occurring asthma and chronic bronchitis in a retrospective study using client questionnaires.\textsuperscript{34}

**Analysis of efficacy**

Three cats were withdrawn from the HCA study; two were lost to follow-up and one was removed owing to poor efficacy.\textsuperscript{43} Using an intention-to-treat analysis, there was a 77% reduction in FeDESI score and 76% reduction in pruritus by D56. Over 50% of the improvement was seen by D14. Ease-of-administration, tolerance and efficacy assessments were good-to-excellent in the seven cats that completed the study. Of these cats, six of seven could be maintained on every other day treatment and one required daily therapy.

Although inhaled flunisolide decreased allergen-specific IgE and the number of eosinophils in the BALF of cats experimentally sensitised to Bermuda grass (Table 5),\textsuperscript{66,68} it did not improve airway hyper-reactivity to methacholine.\textsuperscript{66} Fluticasone dosages of 44, 110 or 220 mcg twice daily for three weeks did not suppress the hypothalamic–pituitary–adrenal axis.\textsuperscript{68} In the same experimental model, inhaled fluticasone did not influence the outcome of RIT in contrast to oral glucocorticoids (where airway eosinophilia was significantly increased after nine months of RIT), although the dose of prednisolone was very high.\textsuperscript{65} In the study with the six cats sensitised to \( A. \ suum \), inhaled fluticasone propionate, or a fluticasone propionate and salbutamol combination, resulted in significantly decreased allergen-induced airway hyper-responsiveness. The mean BALF eosinophil percentage was significantly lower after the inhaled combination of fluticasone and salbutamol.\textsuperscript{71} In the study of naturally occurring asthma or chronic bronchitis treated with budesonide, close to a third of the cats were asymptomatic with therapy, almost as many improved (Table 5).\textsuperscript{34} BWBP parameters had improved in the 19 cats where pre- and post-examinations were available.\textsuperscript{34}

**Adverse effects**

In the study using HCA in cats with FASS, no adverse events were noted and there were no haematological, biochemical or urine abnormalities in samples from four of the cats.\textsuperscript{43} Four cats would not tolerate the spray and the solution was applied directly using cotton wool. There was no association between the response to treatment and lesion type. In studies evaluating feline asthma, clinical adverse effects to inhaled glucocorticoids were either not seen\textsuperscript{34,65} or not mentioned.\textsuperscript{66,68,71} Inhaled budesonide therapy was associated with hypothalamic–pituitary–adrenal axis suppression in one study.\textsuperscript{34}

**Recommendations**

Topical 0.0584% HCA was rapidly effective in seven of 10 cats (QOE2; SOR B). It is likely that other topical
glucocorticoids also will be effective depending on the type and formulation of glucocorticoid (QOE 3; SOR C) and topical treatment should be considered for FASS whenever feasible (QOE 3; SOR C). This is likely to have fewer adverse effects than systemic glucocorticoid treatment. However, these products are not licenced for cats, systemic absorption is possible and regular clinical monitoring is advised. There is good evidence that inhaled glucocorticoids are beneficial for cats with asthma (QOE 1; SOR A). No clinical adverse effects were reported, although again monitoring of cats on long-term treatment is advised. Hypothalamic–pituitary–adrenal axis suppression was documented with high doses of inhaled fluticasone and budesonide.

### Ciclosporin

**Analysis of evidence**

Ciclosporin use in FASS was evaluated in two double-blinded, placebo-controlled studies,\(^{42,77}\) one double-blinded, prednisolone-controlled study,\(^{54}\) three prospective open studies,\(^{40,46,88}\) one safety and tolerability study,\(^{18}\) and three retrospective case series.\(^{22,31,33}\) In two studies, specific clinical presentations were not mentioned\(^{22,64}\) while the other studies\(^{31,33,40,46,77}\) included cats with excoriations as a consequence of pruritus \((n = 185),\) self-induced alopecia \((n = 181),\) eosinophilic granuloma \((n = 112)\) and miliary dermatitis \((n = 100).\)

Most cats presented with more than one lesion type. There is one case report of a cat with asthma, congestive heart failure and diabetes mellitus treated successfully with ciclosporin.\(^{14}\) Two other studies evaluated the effect of ciclosporin on mast cell degranulation and airway remodelling in a colony of cats sensitised to *A. suum*.\(^{74,89}\) In older studies, a human product of ciclosporin was used (Neoral, Novartis; Basel, Switzerland),\(^{33,40,64}\) whereas in newer studies, the veterinary product was administered (Atopica, Novartis) and in one study both products were used.\(^{31}\)

**Analysis of efficacy**

Two double-blinded, placebo-controlled studies,\(^{42,77}\) one double-blinded, prednisolone-controlled study,\(^{54}\) three prospective open studies,\(^{40,46,88}\) and two retrospective case series,\(^{31,33}\) reported the treatment outcome in 328 cases of FASS. In general, ciclosporin was effective in 40–100% of the cats. However, scoring systems for the lesions varied. Many studies used a validated score such as the SCORFAD,\(^{42,46,88}\) and others used the Feline Eosinophilic Granuloma, Eosinophilic Plaque, Extension and Severity Index (FEGEPESI),\(^{49}\) or a score devised as a total lesion score (TLS) describing the extent and severity on a scale from 0 to 4 for each of the major reaction patterns seen in FASS.\(^{77}\) One study\(^{64}\) used a CADESI-02 score validated for cAD.\(^{90,91}\) Owner-assessed pruritus was evaluated in most studies using a pVAS\(^{40,46,77,88}\) yet one study used a scale from 1 to 5,\(^{44}\) and another used a scale from 1 to 10.\(^{33}\) The latter study also evaluated the lesions on a 1–10 scale.\(^{33}\) Only two studies used owner global assessments.\(^{42,77}\) Finally, one retrospective study did not consider pruritus or lesions, and rather evaluated the owners’ impressions of various treatments.\(^{31}\) One study\(^{88}\) was a follow-up of a double-blinded, placebo-controlled study and evaluated tapering schedules for ciclosporin in cats.\(^{42}\) During the final four weeks of that particular study, 63%, 22% and 15% of 157 cats could be maintained on twice-weekly, every other day or daily treatment, respectively.\(^{42}\) Likewise, in another open study ciclosporin could be tapered to every other day in 15% and twice weekly in 57% of the cats.\(^{46}\) Results of the various studies are listed in Table 6.

Ciclosporin did not affect mast cell degranulation or the early asthmatic response in *A. suum*-sensitised cats with induced asthma.\(^{74}\) However, in another study by the same group, ciclosporin was shown to reduce airway reactivity and remodelling after chronic antigen challenge in cats sensitised to *A. suum*.\(^{89}\) Ciclosporin also was used in a cat with feline asthma and concurrent congestive heart failure and diabetes mellitus at a dosage of 4 mg/kg twice daily.\(^{14}\) Clinical signs and airway eosinophilia resolved completely within three weeks of therapy. However, thereafter the ciclosporin was replaced with inhaled fluticasone and long-term effects of the ciclosporin could not be evaluated.\(^{14}\)

**Adverse effects**

In all studies, gastrointestinal signs were the most common adverse effects. In one study, vomiting, diarrhoea

### Table 5. Responses to inhaled glucocorticoids in 67 cats with asthma

<table>
<thead>
<tr>
<th>Inhaled glucocorticoid (number of cats evaluated)</th>
<th>Dosage</th>
<th>Response</th>
<th>Reference Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budesonide ((n = 43))</td>
<td>400 mcg twice daily for less than two months</td>
<td>Clinical improvement in 23/43, lower basal Penh, higher PCPenh300</td>
<td>Galer 2013 (\text{ReSt})</td>
<td>2</td>
</tr>
<tr>
<td>Fluticasone ((n = 6))</td>
<td>220 mcg twice daily for six months concurrent to ASIT</td>
<td>Decrease in BALF eosinophilia and airway inflammation</td>
<td>Chang 2013(^{26}) (\text{RCT})</td>
<td>1</td>
</tr>
<tr>
<td>Fluticasone ((n = 6))</td>
<td>500 mcg twice daily for one month</td>
<td>Decrease in airway hyperresponsiveness</td>
<td>Leemans 2012(^{71}) (\text{RCT})</td>
<td>1</td>
</tr>
<tr>
<td>Fluticasone ((n = 6))</td>
<td>44 mcg twice daily, 110 mcg twice daily and 220 mcg twice daily in a cross-over design</td>
<td>Reduction of airway eosinophilia</td>
<td>Cohn 2010(^{48}) (\text{RCT})</td>
<td>1</td>
</tr>
<tr>
<td>Flunisolide ((n = 6))</td>
<td>250 mcg twice daily for two weeks</td>
<td>Decrease in BALF eosinophilia</td>
<td>Reinero 2005(^{56}) (\text{RCT})</td>
<td>1</td>
</tr>
</tbody>
</table>

ASIT allergen (-specific) immunotherapy, BALF bronchoalveolar lavage fluid, Penh enhanced pause, QOE quality of evidence, RCT randomised controlled trial, ReSt retrospective study.
and/or anorexia was noted in 12 of 50 and weight loss in eight of 50 cats. Gingival hyperplasia, a known adverse effect in dogs, occurred once. In one study, vomiting occurred in 26 of 65 and diarrhoea in 13 of 65 cats. In another study, diarrhoea was more common (in five of 18) than intermittent vomiting (three of 18). Two gastrointestinal adverse effects are reported in dogs,94 gastrointestinal adverse effects are significantly associated with systemic administration of ciclosporin in cats in a larger study evaluating 12 patients that had developed this disease in a population of 70,167 cats.93

### Table 6. Responses to ciclosporin treatment in 328 feline atopic skin syndrome (FASS) cases

<table>
<thead>
<tr>
<th>Type of ciclosporin (number of cats evaluated)</th>
<th>Dosage</th>
<th>Responses*</th>
<th>Global Assessment</th>
<th>References Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ciclosporin microemulsion liquid (Novartis)</strong> (n = 144)</td>
<td>7 mg/kg once daily for 42 days</td>
<td>Mean (SD) 7.3 (3.0) to 2.5 (2.8)</td>
<td>Mean (SD) 69 (22) to 28 (28)</td>
<td>69% successful response</td>
<td>Roberts et al. 2016RCT</td>
</tr>
<tr>
<td>Neoral capsules or ciclosporin microemulsion liquid (Novartis) (n = 10)</td>
<td>Only mentioned in three cats: 2–4 mg/kg once daily</td>
<td>Good response in all cats</td>
<td>N/A</td>
<td>Ravens et al. 2014ReSt</td>
<td>2</td>
</tr>
<tr>
<td><strong>Ciclosporin microemulsion liquid (Novartis)</strong> (n = 65)</td>
<td>7 mg/kg once daily for four weeks</td>
<td>Mean (SD) 7.3 (3.5) decreased to 2.3 (2.7) in first 28 days</td>
<td>Mean (SD) 66 (23) decreased to 26 (29)</td>
<td>N/A</td>
<td>Steffan et al. 2013RCT</td>
</tr>
<tr>
<td><strong>Ciclosporin microemulsion liquid (Novartis)</strong> (n = 32)</td>
<td>2.5 mg/kg once daily for six weeks</td>
<td>Mean (SD) 6.8 (2.8) decreased to 1.8 (1.5); 15 improvement &gt; 50%</td>
<td>Mean (SD) 69 (36), 13 improvement &gt; 50%</td>
<td>Mean (SD) 1.8 (1.5)</td>
<td>King et al 2012RCT</td>
</tr>
<tr>
<td><strong>Ciclosporin microemulsion liquid (Novartis)</strong> (n = 33)</td>
<td>7 mg/kg once daily for six weeks</td>
<td>Mean (SD) 7.7 (3.9) decreased to 2.9 (2.7); 23 improvement &gt; 50%</td>
<td>Mean (SD) 66 (31), 21 improvement &gt; 50%</td>
<td>Mean (SD) 1.4 (1.4)</td>
<td>King et al 2012RCT</td>
</tr>
<tr>
<td>Neoral capsules (Novartis) (n = 18)</td>
<td>5 mg/kg daily for 28 days</td>
<td>Improvement by 38% (SD 45%), 13/18 improvement by &gt; 25%</td>
<td>Pruritus improved in 61%</td>
<td>N/A</td>
<td>Wisselink et al. 2009RCT</td>
</tr>
<tr>
<td>Neoral capsules (Novartis) (n = 10)</td>
<td>4–8 mg/kg once daily for 30 days</td>
<td>FEGEPESI decreased from 7.5 to 3.6, 5 improvement &gt; 50%</td>
<td>Decreased from 8.5 to 4.6, 4 improvement &gt; 50%</td>
<td>N/A</td>
<td>Noli et al. 2006Case series</td>
</tr>
<tr>
<td>Neoral capsules or solution (n = 16)</td>
<td>6.4–12.3 mg/kg per day for 90 days</td>
<td>All cats but 1 cured (1 euthanasia)</td>
<td>N/A</td>
<td>Vercelli et al. 2006ReSt</td>
<td>2</td>
</tr>
</tbody>
</table>

FEGEPESI Feline Eosinophilic Granuloma, Eosinophilic Plaque, Extension and Severity Index, QOE quality of evidence, RCT randomised controlled trial, ReSt retrospective study.

* See text for details of the outcome measures.

† 0 = excellent, 1 = good, 2 = acceptable, 3 = poor, 4 = bad.
influence the treatment decision in seronegative cats with access to outdoors or fed raw meat (QOE2; SOR B).

**Oclacitinib**

**Analysis of evidence**

One case report,10 two open prospective studies24,41 and one methylprednisolone-controlled double-blinded study62 reported the efficacy of oclacitinib for FASS. These included 68 cats, 48 of whom were treated with oclacitinib. In one abstract, details of the improvements were not given.24 The outcome measures of the other two prospective studies were a clinician-assessed lesional score, the SCORFAD and an owner-based pVAS.41,62 One study did not specify the lesion type,62 and the other studies included 19 cats with excoriations on the head and neck, eight cats with self-induced alopecia, four cats with eosinophilic granuloma and one cat with miliary dermatitis.10,24,41 Most cats presented with more than one lesion type. Seasonality was not recorded for any cat. In a randomised, placebo-controlled study, 24 cats with induced asthma experimentally sensitised to Bermuda grass received oclacitinib at 0.5 or 1.0 mg/kg twice daily for four weeks and airway inflammation was monitored.26 In addition, a more recent study documented a more rapid elimination of oclacitinib in the cat versus the dog, and recommended a shorter dose interval and/or higher doses of oclacitinib in cats compared to dogs.19

**Analysis of efficacy**

Treatment outcome data were available for all 48 cats with FASS (see Table 7). Cats that responded to treatment were reported to do so within one month. Overall, a good response was reported at a dosage of 1 mg/kg once or twice daily. One third of the cats had a good-to-excellent response in one study.41 In one case report with long-term follow-up, the cat achieved long-term clinical remission while on therapy.10

In the study evaluating the two doses of oclacitinib (0.5 or 1.0 mg/kg twice daily) in cats with experimental asthma, the percentage of eosinophils in BALF was significantly decreased compared to placebo with no difference between the two dosages.26 There was no significant difference between treatment groups in the effective concentration of methacholine that induced a 200% increase over baseline airway resistance.26

**Adverse effects**

Adverse effects were not specifically recorded in two studies,24,41 although in one study owners reported the drug to be clinically well-tolerated by all cats.41 In another study, at least half of the cats were monitored with complete blood counts and serum biochemistry with neutropenia seen in two, thrombocytopenia in one, increased blood urea nitrogen and creatinine in four, and increased alanine aminotransferase in three cats.62 In the case report monthly serum biochemistries and complete blood counts for 10 months did not show any changes.10 In a recent placebo-controlled safety study, oclacitinib was administered at 1 and 2 mg/kg twice daily for 28 days.95 Vomiting and soft stools were noted in two of 10 cats each in the high-dose group. A small increase in fructosamine concentrations was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no differences in individual parameters in complete blood counts and biochemistry panels. In the study of cats with experimental asthma, no adverse effects were noted in the four weeks of treatment.26

**Recommendations**

Oclacitinib at a dosage of approximately 1 mg/kg once or twice daily was an efficacious treatment option for FASS (QOE1; SOR A). Based on the small number of cats and the short duration of most studies as well as the lack of long-term safety data and the off-label use of the drug, cats receiving oclacitinib should be monitored closely until...

---

**Table 7. Responses to oclacitinib treatment in 48 cats with feline atopic skin syndrome (FASS)**

<table>
<thead>
<tr>
<th>Dose (number of cats evaluated)</th>
<th>Global efficacy by owner</th>
<th>SCORFAD; MEAN (SD)</th>
<th>pVAS; mean (SD)</th>
<th>References Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.7–1.2 mg/kg twice daily for 28 days (n = 20)</td>
<td>11 Good–excellent–marked 4 Poor 5</td>
<td>6.2 (2.3) and 2.4 (2) before and after; &gt;50% in 12</td>
<td>7.5 (1.5) and 3.4 (3) before and after; &gt;50% in 15/20; &gt;2 cm in 11</td>
<td>Noli et al. 201962 RCT</td>
<td>1</td>
</tr>
<tr>
<td>1 mg/kg twice daily for 14 days, then once daily for 300 days, then twice daily (n = 1)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Remission after 30 days, relapse after 300 days on once daily, and then remission again on twice daily</td>
<td>Fernandes et al. 201910 Case reports</td>
</tr>
<tr>
<td>0.5–0.8 mg/kg twice daily for 14 days, then once daily (n = 15)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>10 improved†</td>
<td>Pandolfi et al. 201624 Case series</td>
</tr>
<tr>
<td>0.4–0.6 mg/kg twice daily for 14 days, then once daily for 14 days (n = 12)</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>4.9 (2.4) and 3.6 (3) before and after</td>
<td>Ortalda et al. 201541 Case series</td>
</tr>
</tbody>
</table>

pVAS pruritus Visual Analog Scale, QOE quality of evidence, RCT randomised controlled trial, ReSt Retrospective study, SCORFAD Scoring Feline Allergic Dermatitis.

†No further details were given in the abstract.

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology, 32, 43–e8.
Bronchodilators

Analysis of evidence

One study evaluated salbutamol, ipratropium bromide and the combination of those two drugs in cats sensitised to ovalbumin and to A. suum compared to control cats.69 In another study, the same drugs were used in a double-blinded, placebo-controlled cross-over design in A. suum sensitised cats.70 In a clinical study including 19 cats with naturally occurring bronchial disease, therapy with low-dose prednisolone was supplemented with propentofylline in 10 cats.57

Analysis of efficacy

In the first study, cats sensitised to ovalbumin (n = 6), to A. suum (n = 6) and nonsensitised control cats (n = 6) were evaluated.69 Salbutamol (100 mcg, two puffs), ipratropium bromide (20 mcg, two puffs) or a combination of salbutamol and ipratropium bromide (120 mcg/20 mcg, two puffs) were administrated to the conscious cats by use of a pressurized metered-dose inhaler and a spacing chamber connected through an inspiratory valve to a facemask. Salbutamol/ipratropium bromide reduced BAL-induced bronchoconstriction in the cats sensitised to A. suum, and not in the cats sensitised to ovalbumin or control cats. By contrast, salbutamol or ipratropium bromide alone did not lead to any significant changes.69 In the cross-over study with five cats sensitised to A. suum, enhanced pause, an estimator of airflow limitation measured by BWBP, was repeatedly assessed within 120 min following the administration of each treatment protocol.70 Responses to inhaled medications were evaluated by calculating the area under the time–response curves (AUC) from 0 to 60 or 120 min after drug administration (AUC0–60, AUC0–120), as well as the times required for half-recovery or for returning to nearly basal conditions. There was no difference in time-related bronchodilating effects between 100 mcg salbutamol, 20 mcg ipratropium bromide, a combination of the two treatments, and the nontreated control.70 Cats treated with a combination of propentofylline and prednisolone significantly improved in their auscultation scores, respiratory pattern scores and radiological bronchial markings score over the observation period, and they coughed less and were more active at the end of the study compared to the cats treated with prednisolone alone.97

Adverse effects

No adverse reactions occurred in one study.69 Adverse effects were not mentioned in two.57,70

Recommendations

Although bronchodilators are frequently recommended for the treatment of feline asthma,96,97 the two evaluated studies provided no evidence supporting the use of bronchodilators in asthmatic cats (QOE2; SOR B). Moreover, both trials were with cats experimentally sensitised in the laboratory and studies evaluating bronchodilators in cats with naturally occurring asthma are lacking. Despite this, inhaled bronchodilators are recommended for management of acute asthmatic episodes and for long-term treatment of feline asthma alongside inhaled steroids (QOE3; SOR C). Clearly, further studies on the efficacy of bronchodilators are needed.

H1-receptor blocking antihistamines

Analysis of evidence

There were seven open and uncontrolled studies reporting the efficacy of H1R-antihistamines in FASS; six were prospective36–38,44,45,51 and one was retrospective.31 One study was prospective, double-blinded and placebo-controlled.63 These included 164 cats: 37 treated with cetirizine and clemastine fumarate,38 20 with cypiroheptadine hydrochloride,45 51 with cetirizine66,67 and 46 with loratidine.31,51 The outcome measures varied with the five prospective studies using owner-assessed pVAS (reductions of 0–25% poor, 26–50% fair, 51–75% good and 76–100% excellent in four studies; and ≤25% mild, 25–50% moderate and ≥50% marked in one study). The retrospective study defined a “good” response as a marked reduction or resolution of clinical lesions and reduction or discontinuation of ongoing symptomatic medications, a “partial” as a reduction in clinical lesions with ongoing antipruritic drugs, and “no response” with no apparent change to lesions, pruritus and/or symptomatic medications. The cats presented with pruritus and a variety of the recognised reaction patterns associated with FASS. Most cats presented with more than one type of lesion. Seasonality was recorded for 99 cats, with 90 having perennial disease and nine seasonal disease. Two studies evaluated cetirizine and cypiroheptadine in a model of feline asthma.66,67 Unfortunately, only two studies reported pharmacokinetic data of antihistamines in cats.20,21 Oral cypiroheptadine was well-absorbed and had a half life of approximately 12 h.20 Cetirizine was well-absorbed after oral administration, with higher plasma concentrations than seen in humans and a half-life compatible with once-daily dosing.21

Analysis of efficacy

Treatment outcome data were available for 164 cats with FASS (see Table 8). Cats that responded to treatment were reported to do so within three to 10 days of starting treatment and to relapse within two to three days of stopping. There was no association between the responses to treatment and the type of lesions or seasonality. A retrospective study31 (QOE 3) reviewed type 1 antihistamine treatment in 31 cats. However, with the exception of cetirizine (n = 19) and loratidine (n = 18) (outcomes included in Table 6), specific treatments and outcomes were not reported. Most cats received more than one antihistamine with variable and inconsistent results. Overall, a good response was reported in two of 31, a partial response in 20 of 31, and a poor response in nine of 31 cats.31
When used in a model of feline asthma, antihista-
mines such as cetirizine and cyproheptadine did not
alter percentage of eosinophils in BALF, or sero-
tonin and histamine concentrations in plasma or
BALF.66,67

Adverse effects
Most of the antihistamines were reported to be well-
tolerated. Adverse effects included sedation in two of
37 cats treated with chlorpheniramine and diarrhea in
one of 10 cats given clemastine. However, adverse
effects were reported in 11 of 20 cats treated with
cyproheptadine; three cats were withdrawn from treat-
ment (one with vomiting, two with polyphagial and
adverse effects were reported in another eight cats
(vomiting in one, polyphagia in four and altered beha-
viour/vocalisation in four).

Recommendations
Oral antihistamines could provide a small and limited
benefit in some cats with FASS and this is not likely
to result in good-to-excellent response in most cases
(QOE 2; SOR B). The available evidence supports the
use of chlorpheniramine as a first-line H1R-antihis-
tamine (QOE 2; SOR B). The mode of action of these
drugs in cats is unknown yet, based on recommenda-
tions in cAD,8 it is likely that they will be most effec-
tive in early and/or mild disease and when given
proactively rather than reactively to manage an acute
exacerbation (QOE3; SOR C). It is also possible that
the sedative effect of first generation H1R-antihista-
mes may alleviate stress-associated triggers in FASS
(QOE3; SOR C). The high frequency of adverse
effects to cyproheptadine is of concern (QOE2; SOR
B). There is no evidence supporting the use of antihis-
tamines in cats with asthma (QOE2; SOR B).

Essential fatty acids and palmitoylethanolamide

Analysis of evidence
Treatment outcome data were available for 37 cats with
FASS (see Table 9). In one prospective, double-blinded,
placebo-controlled study 15 cats either received evening
primrose oil (EPO) or olive oil as the placebo for 12
weeks.61 There was one prospective, double-blinded, pla-
cebo-controlled study evaluating 15 cats with FASS,61
two randomised studies with 1153 and 1453 atopic cats,
one prospective study with 10 cats with FASS (and 18
cats with food allergy, flea bite hypersensitivity or miliary
dermatitis, self-induced alopecia or eosinophilic granu-
loma without further diagnostic work-up)59 and 12 cats
with miliary dermatitis,59 respectively. In another study,
healthy cats were given essential fatty acids as a supple-
ment to a standard diet.98 In some studies, cytological
evaluation, fungal cultures, skin scrapings, flea control and
elimination diets were performed as needed before inclu-
sion to confirm the diagnosis of FASS.53,54,61 In others,
cats showed clinical features of FASS, and differential
diagnoses were not55 or not always39 evaluated. In three
studies, only cats with miliary dermatitis (n = 30) were
included.53,55 In an open label study, 15 cats with nonflea-
associated FASS were given 10 mg/kg ultramicronised
palmitoylethanolamide (PEAum) twice daily for 30 days.
The outcome measures were a clinical assessment (prur-
tus, erythema, alopecia, and extent of eosinophilic pla-
ques and granulomas) and evaluation of mast cell
numbers in skin biopsies.50 One double-blinded, placebo-
controlled randomised trial assessed the efficacy of
PEAum in maintaining remission in cats with nonseasonal
pruritus and FASS (described as nonflea-associated hyper-
sensitivity dermatitis with a variety of reaction patterns).99
The cats initially were stabilised with two weeks of
methylprednisolone (4–6 mg/cat/day) and then main-
tained on PEAum (n = 21; approximately 15 mg/kg/day)

Table 8. Responses to antihistamine treatment in 164 cats with feline atopic skin syndrome (FASS)

<table>
<thead>
<tr>
<th>Antihistamine (number of cats evaluated)</th>
<th>Dose</th>
<th>Responses*</th>
<th>Good–excellent–marked</th>
<th>Partial–moderate–fair</th>
<th>Poor–mild</th>
<th>References</th>
<th>Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loratadine (n = 48)</td>
<td>5 mg/cat once daily for 14 days</td>
<td>4%</td>
<td>17%*</td>
<td>79%</td>
<td>Ravens et al 201451</td>
<td>ReSt Scott et al 201551</td>
<td>Case series</td>
<td>3 2</td>
</tr>
<tr>
<td>Cetirizine (n = 19)</td>
<td>1 mg/kg once daily for 28 days</td>
<td>0%</td>
<td>11%</td>
<td>89%</td>
<td>Wildermuth et al 201353</td>
<td>RCT</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cetirizine (n = 32)</td>
<td>5 mg/cat once daily for 14 days</td>
<td>9%</td>
<td>16%</td>
<td>75%*</td>
<td>Griffin et al 201256</td>
<td>Case series</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Cyproheptadine HCl (n = 20)</td>
<td>2 mg/cat twice daily for 14 days</td>
<td>45%</td>
<td>0</td>
<td>55%</td>
<td>Scott et al 199655</td>
<td>Case series</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Chlorpheniramine (n = 37)</td>
<td>2 mg/cat twice daily for 14 days</td>
<td>70%</td>
<td>0</td>
<td>30%</td>
<td>Miller and Scott 199057</td>
<td>Case series</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Clemastine fumarate (n = 10)</td>
<td>0.34 mg/cat twice daily for two weeks, then 0.68 mg/cat twice daily for two weeks</td>
<td>50%</td>
<td>0</td>
<td>50%</td>
<td>Miller and Scott 199458</td>
<td>Case series</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Mean outcomes 36% 6% 58%  

QOE quality of evidence, RCT randomised controlled trial, ReSt Retrospective study.
1See text for the definitions of the responses to treatment.
2Five of 11 nonresponders were concurrently treated with an omega3/omega6 essential fatty acid supplement.
3Median pruritus scores decreased from 5.25 to 5 (all cats) or 2.75 (responders).
4Includes five cats with a mild improvement; *all in one retrospective study.51

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology. 32, 43–e8.
or placebo (n = 23) alone. The outcome was the time to relapse (≥2 point increase and/or score ≥ 4 in SCORFAD, ≥2 cm increase in pVAS or global assessment score of 3 (0–3 scale)). One study assessed the preventive effects of omega-3 polyunsaturated fatty acids (omega3 PUFA) and lutein supplementation on allergen-induced airway inflammation in eight A. suum-sensitised cats.49

Analysis of efficacy
In one prospective, double-blinded, placebo-controlled study, 15 cats either received evening primrose oil (EPO) or olive oil as the placebo for 12 weeks.61 Mean pruritus, erythema, alopecia and overall scores did not improve significantly, nor was there a significant difference between groups. Two owners in each group considered their cats partially improved.61 In another randomised study, 11 cats received either EPO (n = 6) or sunflower oil (n = 5) for 12 weeks. Mean overall clinical, self-trauma and crusted papule scores decreased by >50% in both groups.54 In another study evaluating 14 cats with miliary dermatitis, seven of 14 showed good improvement after six weeks of 0.5 mL EPO/cat once daily.53 When combined with fish oil for another six weeks, 11 of 14 cats showed a good response (the “good response” was not further defined). When given fish oil for another six weeks without the EPO, clinical signs recurred in 10 of 11 cats.53 Five healthy cats and five cats with miliary dermatitis, seven of 14 showed good improvement after 12 weeks. Cutaneous reactions to histamine were increased. No adverse effects were noted. In the RCT comparing PEAum and placebo groups,54 in another study evaluating 14 cats with miliary dermatitis resolved in three of five affected cats.55 In a further study, healthy cats were given a fish oil (FO; EPA and DHA) or a flax seed oil (FSO; α-linolenic acid (ALNA, 18:3n-3)) supplementation (n = 14 in each group) to a standard diet (n-6:n-3 ratio 20:1) to achieve an n-6:n-3 ratio of 5:1.98 The supplements and diets were given for 12 weeks. Cutaneous reactions to histamine were reduced by 20–40% after FO and by 50% after FSO. FO raised leukotriene B (LTB) 5 levels and decreased the LTB4:LTB5 ratio; and FO and FSO decreased B, T-helper and total T-cell numbers, as well as proliferation to pokeweed mitogen. However, there was no effect on T-cytotoxic, natural killer and MHC class II cells, delayed type (type 4 cell-mediated) hypersensitivity, IL-2 expression or plasma IgG concentration, or concanavalin A or phytohaemagglutinin-triggered stimulation. No adverse effects were reported in any of these studies. In the uncontrolled trial of PEAum, pruritus/erythema/alopieca improved in 64.3% of the cats and eosinophilic dermatitis lesions in 66.7% (three of 15 completely resolved). There was no change in mast cell numbers, although their granularity increased. No adverse effects were noted. In the RCT assessing maintenance of methylprednisolone-induced remission of FASS, the mean time to relapse was significantly longer in the PEAum group (40.5 days; 13 of 19 cats relapsed) than the placebo group (22.2 days; 12 of 22 cats relapsed). Pruritus scores were significantly lower in the PEA-treated cats and there was no difference in lesion scores. Gastrointestinal effects were seen in four PEAum-treated cats (two withdrawn) and six placebo-treated cats (one withdrawn).

When eight asthmatic cats sensitised to A. suum received four weeks of omega-3 fatty acids (20 mg once daily) and luteolin (10 mg once daily), analysis of BALF total and differential cell counts did not reveal any significant differences between treated and untreated A. suum-stimulated cats.49 However, concentrations of leukotriene A4 increased and airway responsiveness decreased after the supplement intake.49

Recommendations
Based on available data, there is limited evidence for moderate efficacy of EFA supplementation in cats with miliary dermatitis (QOE2; SOR B). A single study in healthy cats showed decreased reactivity to histamine with variable and moderate suppression of B- and T-cell function.98 However, the clinical relevance of these findings remains unknown. There is moderate evidence of moderate efficacy for PEAum in FASS (QOE2; SOR B). There is insufficient evidence for the benefit of EFAs or PEAum in feline asthma.

Maropitant
Analysis of evidence
One open study evaluated maropitant at 2 mg/kg orally once daily for four weeks as treatment for cats with FASS.52 Two randomised, placebo-controlled studies looked at the effect of maropitant on acute and chronic asthma, respectively, in experimentally sensitised cats.78,79

Analysis of efficacy
Maropitant decreased SCORFAD from 7.8 to 2.2 and pruritus scores from 7.1 to 2.3, respectively, in 12 cats with FASS.52 Ten of those cats improved by >50% in lesions, and 11 of 12 by >50% in pruritus.

When administered to artificially sensitised cats with feline asthma at 2 mg/kg subcutaneously immediately after allergen challenge, maropitant did not diminish clinical scores or airway eosinophilia.79 Likewise, there was no difference in clinical scores or airway eosinophilia when sensitised cats were administered maropitant at 2 mg/kg every 48 h for four weeks, although daily administration was not evaluated.78

Adverse effects
Increased salivation immediately after maropitant administration occurred in two of 12 cats with FASS.52

Recommendations
There is limited evidence of good efficacy for maropitant in FASS (QOE2; SOR B). There is currently no evidence supporting the use of maropitant in cats with asthma (QOE1; SOR A).

Antibiotics
Analysis of evidence
There was one double-blinded, placebo-controlled study on the efficacy of oral amoxicillin-clavulanate...
**Analysis of efficacy**

Treatment with amoxicillin-clavulanate significantly reduced the mean lesion size of the eosinophilic plaques by 96% and indolent ulcers by 43% compared to the placebo (0% and 37% increases, respectively). There was also a decrease in the number of high-power microscope fields with cytological evidence of infection of 80% in the eosinophilic plaque group and 65% in the indolent ulcer group compared to placebo (16% decrease and 13% increase, respectively).

It needs to be pointed out that eosinophilic plaques, indolent ulcers and linear granulomas are reaction patterns associated with other underlying allergic and nonallergic causes, and those cats were diagnosed with secondary bacterial infections. In cats with asthma, four days of doxycycline did not influence the early or late asthmatic response.

**Recommendations**

The small and well-conducted study in FASS provided evidence of high efficacy of amoxicillin-clavulanate in eosinophilic plaques and indolent ulcers (QOE 1, SOR A). However, it is unclear whether the improvement was the result of eliminating the bacteria from the lesions and/or immunomodulation, and whether treatment resulted in a sustained response. In addition, current antimicrobial treatment guidelines for skin infections (summarised in Brisso, 2016) emphasise using topical antimicrobial therapy over systemic treatment and, where this is necessary, using the lowest tier, most narrow-spectrum drug possible for the shortest time required to clear the infection. Long-term therapy in the absence of a bacterial infection usually is discouraged, and veterinarians are advised to follow antimicrobial treatment guidelines established in their country of practice and/or in international consensus recommendations. So far, no evidence has been published supporting the use of antibiotics in feline asthma (QOE 2, SOR B).

Inhaled lidocaine.

**Analysis of evidence**

Nebulised lidocaine has received interest as a corticosteroid-sparing drug in human asthmatics, reducing airway resistance and peripheral blood eosinophilia. It was evaluated in healthy and experimentally asthmatic cats in a cross-over study. Five healthy and nine experimentally asthmatic cats received nebulised lidocaine at the dose of 2 mg/kg three times a day for two weeks in a cross-over design.

**Analysis of efficacy**

In healthy cats, lidocaine did not significantly alter BALF eosinophilia or the concentration of methacholine increasing baseline airway resistance by 200%. There was no difference in eosinophil percentages in the BALF in asthmatic cats treated with lidocaine (36 ± 10%) or placebo (33 ± 6%). However, lidocaine significantly increased the concentration of methacholine increasing baseline airway resistance by 200% compared with placebo (10 ± 2 versus 5 ± 1 mg/mL). Adverse effects were not seen with nebulized lidocaine.

**Recommendations**

Based on this one study, lidocaine may serve as an adjunctive therapy in feline asthmatics with mild beneficial effects on airflow obstruction (QOE 2; SOR B).

**Mesenchymal stem cell therapy**

**Analysis of evidence**

Adipose-derived mesenchymal stem cells (MSC) were evaluated in a small RCT in an experimental feline asthma model. In this pilot study, allogenic adipose-derived MSCs were administered in five intravenous infusions at D0, D14, D28, D98 and D130 to four of six cats experimentally sensitized with Bermuda grass while two cats were treated with placebo. BALF eosinophilia was evaluated at seven time points over nine months, along with blood samples to evaluate T-lymphocyte phenotype, total Bermuda grass allergen-specific lymphocyte proliferation, IL-10 production from lipopolysaccharide (LPS)-stimulated whole blood, and numbers of IL-10-producing cells. Additionally, thoracic computed tomography (CT) in conjunction with abbreviated pulmonary function testing was compared to that of healthy cats used as controls.

**Analysis of efficacy**

Diminished airway hyper-responsiveness was noted in all MSC-treated compared with the placebo-treated cats at D133. Lung attenuation and bronchial wall-thickening scores consistent with decreased airway remodelling were significantly reduced in MSC-treated versus untreated asthmatic cats.

**Recommendations**

There is limited evidence of mild-to-moderate long-term efficacy of MSC in the treatment of feline asthma (QOE 2; SOR B).

**Discussion**

To the best of the authors’ knowledge, this is the first systematic review of therapeutic interventions for the feline atopic syndrome, both for FASS and feline asthma. Such reviews are standard practice in similar human and canine conditions, where the evidence is used as a base for treatment guidelines. The data evaluated in this review have been used to provide a summary of treatment recommendations (Table 10). Clinicians should note that these recommendations do not imply that all of the listed treatments should be used in all patients, nor that they should be considered in this order.
Clinical manifestations of FASS are common problems that decrease the QoL of affected cats and their owners. They appear to be chronic conditions that require long-term management. It is therefore important to eliminate fleas, *Demodex gatoi*, and other ectoparasites and endoparasites, food allergens, bacterial skin infection/pyoderma, yeast overgrowth and differential diagnoses before making a final diagnosis. It also is likely that FASS and feline asthma have a multifaceted aetiology. As in cAD and human asthma, treatments may need to be combined to optimise the outcome for each cat. Clinical trials usually are designed to evaluate the efficacy of a single treatment and therefore may underestimate the efficacy of combination treatment.

Treatment should be tailored to each cat, taking into account the severity, type and distribution of the lesions, and stage of the dermatitis and airway disease. It is likely that most cats will require more potent treatment (e.g. systemic glucocorticoids, topical and inhaled glucocorticoids, ciclosporin or oclacitinib) initially to induce remission. Treatment can then be tapered and/or switched to less potent treatments (e.g. ASIT, essential fatty acids and antihistamines) to maintain the remission.

These treatment recommendations should not be read as a “diktat”, particularly considering the facts that many products are not approved for cats, pharmacokinetic data and dose-finding studies are lacking for most products.

### Table 9. Responses to treatment with fatty acids in 37 cases with feline atopic skin syndrome (FASS)

<table>
<thead>
<tr>
<th>Fatty acids (number of cats evaluated)</th>
<th>Dose</th>
<th>Responses†</th>
<th>References Type of study</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evening primrose oil (n = 7)</td>
<td>0.5 mL/cat once daily</td>
<td>2/7 5/7</td>
<td>Logas and Kunkle 1993⁻⁵¹</td>
<td>1</td>
</tr>
<tr>
<td>Evening primrose oil/fish oil (n = 14)</td>
<td>0.5 mL/cat once daily</td>
<td>11/14</td>
<td>Harvey 1993⁻⁵³ Open study</td>
<td>2</td>
</tr>
<tr>
<td>Evening primrose oil (n = 6)</td>
<td>0.25 mL/cat once daily for 12 weeks</td>
<td>Mean overall clinical scores decreased from 7 to 2.2, self trauma scores from 50 to 12 and crusted papule score from 8 to 2</td>
<td>Harvey 1993⁻⁵⁴ RCT</td>
<td>2</td>
</tr>
<tr>
<td>DVM Derm Cap Liquid (n = 10)</td>
<td>0.2 mL/kg once daily for 14–44 days</td>
<td>5/10 5/10</td>
<td>Miller and Scott 1993⁻⁵⁹ Case series</td>
<td>2</td>
</tr>
<tr>
<td>Mean outcomes</td>
<td>52% 6% 42% ‡</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

QOE quality of evidence, RCT randomised controlled trial.

† See text for details of the outcome measures.

‡ In one study, only the good-to-excellent responders were mentioned and it is unclear if the residual three cats were partial or poor responders and in order not overestimate the treatment benefits of EFAs we assumed that the residual cases showed a poor response.

### Table 10. Summary of treatment recommendations for cats with atopic syndrome

<table>
<thead>
<tr>
<th>Treatment or intervention</th>
<th>Recommendation</th>
<th>QOE</th>
<th>SOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergen avoidance</td>
<td>Limited evidence of moderate efficacy in feline asthma Insufficient evidence in FASS</td>
<td>3</td>
<td>C</td>
</tr>
<tr>
<td>Allergen immunotherapy</td>
<td>Limited evidence of moderate (feline asthma) to good (FASS) efficacy</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Systemic glucocorticoids</td>
<td>Satisfactory evidence of good efficacy in FASS and feline asthma</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Topical glucocorticoids:</td>
<td>Limited evidence of good efficacy in FASS</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Hydrocortisone aceponate</td>
<td>Satisfactory evidence of good efficacy in feline asthma</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Inhaled glucocorticoids</td>
<td>Satisfactory evidence of good efficacy in FASS</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>Satisfactory evidence of good efficacy in FASS Insufficient evidence in feline asthma</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Oclacitinib</td>
<td>Limited evidence of good efficacy in FASS</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>Limited evidence of low efficacy in feline asthma</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Oral H1R-antihistamines</td>
<td>Recommended for acute asthma attacks Limited evidence of poor efficacy in feline asthma Clinical use alongside inhaled glucocorticoids</td>
<td>3</td>
<td>C</td>
</tr>
<tr>
<td>Essential fatty acids</td>
<td>Limited evidence of moderate efficacy in FASS (miliary dermatitis)</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>PEAuM</td>
<td>Limited evidence of moderate efficacy in FASS Insufficient evidence in feline asthma</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Maropitant</td>
<td>Limited evidence of good efficacy in FASS Good evidence of poor efficacy in feline asthma</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>Limited evidence of good efficacy in FASS if there is confirmed infection</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Limited evidence of poor efficacy of doxycycline in asthma</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Inhaled lidocaine</td>
<td>Limited evidence of low efficacy in feline asthma</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Stem cell therapy</td>
<td>Limited evidence of low to moderate efficacy in feline asthma</td>
<td>2</td>
<td>B</td>
</tr>
<tr>
<td>Insufficient evidence in FASS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FAS feline atopic syndrome, FASS feline atopic skin syndrome, QOE quality of evidence, SOR strength of recommendation.
and safety data beyond the studies discussed here also are not available for most drugs. Not every treatment will be effective, tolerated or suitable in every cat. It is up to the individual clinician to evaluate their patient and discuss the advantages and disadvantages of each treatment option with the owners. This will include potential adverse effects, ease-of-administration, and cost as a single treatment or in combination. The owners’ preferences as well as concurrent conditions and medication also will have to be accounted for. Nevertheless, the treatments recommended in this review should be considered before moving to alternatives with less evidence of efficacy and safety in FASS or feline asthma.

The recommendations in this review were derived largely from the results of clinical trials reporting statistically significant changes in various outcome measures. Following best practice, the recommendations were based on SORT scores7 (Table 1), which are a simple and robust way of evaluating patient-orientated outcomes. However, clinicians should note that statistically significant improvements do not necessarily mean that these are clinically significant (i.e. lead to an acceptable improvement in clinical signs and in the QoL for the patient and owner). Moreover, individual animals may have a better or worse response than the mean outcome reported in a clinical trial. In addition, most studies performed on feline asthma utilised small numbers of cats experimentally sensitised to HDN, Bermuda grass or A. suum and more studies are urgently needed assessing treatment options for naturally occurring feline asthma, as well as evaluating adverse effects of those therapies with long-term use.

This review highlights the limited evidence for some treatments in FAS. The analysis of the clinical trials was variously affected by small group sizes, uncontrolled studies, retrospective studies, deficient data reporting, and variable and nonvalidated outcome measures. Compared to the dog, where a rapidly increasing number of randomised, controlled trials are being published, fewer studies of lesser quality are found evaluating allergic cats and more randomised controlled trials are urgently needed. Wherever possible, the quality of clinical trials should be improved by designing double-blinded RCTs, using power calculations to determine adequate treatment cohorts, and using validated outcome measures (e.g. the SCORF AD84,85 and pVAS82 scales or lung function studies), similar to those published for dogs with atopic dermatitis104 and in human asthma.105,106 Other outcome measures relevant to the clinical significance of therapeutic interventions include a QoL score,86 and global scores for efficacy, tolerance and ease-of-administration. Minimum datasets should include intention-to-treat data with means or medians and an appropriate measure of variance (e.g. standard deviation or 95% confidence intervals). Additional useful outcomes include the proportion of cats reaching certain clinical thresholds (e.g. >50% and >75% improvements in pruritus and lesion scores or in lung function). Statistical tests should be appropriate to the data and, where necessary, advice from a statistician should be sought during design of the study.

The recommendations in this review are derived from an evidence-based consensus supporting use of an intervention and do not imply endorsement of specific therapeutic options or products. Furthermore, these recommendations do not consider availability or licensing specifics in individual countries. Clinicians should therefore choose individual treatments based on legal and ethical standards in their own country of practice.

This systemic review of therapeutic interventions has provided evidence for treatment recommendations in FAS (Table 10). It is hoped that these will aid clinicians in designing treatment plans to improve the QoL of their patients and their owners. The review highlighted shortfalls in the quantity and quality of published data. Clinicians are therefore encouraged to publish good quality clinical trials assessing the efficacy of existing and novel treatments. Future reviews including such data will improve the strength and breadth of treatment recommendations for FAS.

Acknowledgements

The authors thank Emmanuel Bensignor, Richard Halliwell, Thierry Olivry, Cherie Pucheu-Haston and Manolis Saridomichelakis for their detailed review of the manuscript. The World Association for Veterinary Dermatology (WAVD) supported the breakfast sessions of the International Committee on Allergic Diseases of Animals (ICADA) at the past European Veterinary Dermatology Congresses and North American Veterinary Dermatology Forums where this paper was planned and the content of the paper discussed.

References


53. Harvey RG. Effect of varying proportions of evening primrose oil and fish oil on cats with crusting dermatosis (‘miliary dermatitis’). Vet Rec 1993; 133: 208–211.


Mueller et al.

93. Pierce KE Jr, Wilkie DA, Gemensky-Metzler AJ et al. An associ-
ation between systemic cyclosporine administration and develop-
94. Steffan J, Favrot C, Mueller R. A systematic review and meta-
analyses of the efficacy and safety of cyclosporin for the treat-
95. Lopes NL, Campos DR, Machado MA et al. A blinded, random-
ized, placebo-controlled trial of the safety of oclacitinib in cats. 
96. Caron I, Carioto L. Feline asthma… a disease that cuts your 
97. Padrid P. Use of inhaled medications to treat respiratory dis-
98. Park HJ, Park JS, Hayek MG et al. Dietary fish oil and flaxseed 
oil suppress inflammation and immunity in cats. Vet Immunol 
99. Noli C, della Valle MF, Miolo Alda et al. Effect of dietary sup-
plementation with ultramicronized palmitoylethanolamide in 
maintaining remission in cats with nonflea hypersensitivity 
dermatitis: a double-blind, multicentre, randomized, 
100. Brisset H, Cervantes S, Guardabassi L et al. GRAM: Guidance 
for the rational use of antimicrobials – recommendations for 
dogs and cats, 2nd edition. Libourne, France: Ceva Santé Ani-
male, 2016: 132–137.
101. Decoo ML, Neenko TA, Hunt LW et al. Nebulized lidocaine in the 
treatment of severe asthma in children: a pilot study. Ann Allergy 
102. Hunt LW, Frigas E, Butterfield JH et al. Treatment of asthma 
with nebulized lidocaine: a randomized, placebo-controlled 
103. Olivry T, DeBoer DJ, Favrot C et al. Treatment of canine atopic 
dermatitis: 2010 clinical practice guidelines from the Interna-
tional Task Force on Canine Atopic Dermatitis. Vet Dermatol 
104. Olivry T, Bensignor E, Favrot C et al. Development of a core 
outcome set for therapeutic clinical trials enrolling dogs with 
105. Wasserfallen JB, Gold K, Schulman KA et al. Development 
and validation of a rhinoconjunctivitis and asthma symptom score 
for use as an outcome measure in clinical trials. Allergy Asthma 
106. Smith SR, Baty JD, Hodge D 3rd. Validation of the pulmonary 
score: an asthma severity score for children. Acad Emerg Med 

Résumé
Contexte – le syndrome atopique félín (FASS) décrit un spectre d’hypersensibilités caractérisées par diverses présentations cliniques comprenant la peau, le système digestif et le système respiratoire. Parmi ces atteintes, il y a le syndrome cutané atopique félín (FASS), pour lequel l’hypersensibilité est typiquement associée à des allergènes environnementaux, bien que l’allergie alimentaire puisse coexister. D’autres organes (par exemple asthme) peuvent aussi être impliqués. En raison de cette grande hétérogénéité clinique, le diagnostic du FASS peut être un défi.

Objectifs – Un sous-groupe de l’ICADA (International Committee on Allergic Diseases of Animals) a été chargé de résumer les informations les plus actuelles sur les présentations cliniques du FASS et de développer des recommandations de diagnostic.

Méthodes – Les citations des bases de données en ligne et les résumés des congrès internationaux ont été recherchés pour les publications en lien avec les allergies félines. Ceci a été combiné avec des opinions d’experts quand nécessaire.

Résultats – Un total de 107 publications pertinentes a été identifié. La compilation de ces données a permis le développement d’une description détaillée des critères cliniques du FASS et le développement de recommandations ciblant une élimination systématique des autres atteintes cutanées avec des caractéristiques cliniques semblables. Alors que les tests allergiques sont fréquemment utilisés par les dermatologues pour soutenir le diagnostic clinique du FASS, une revue rapide de ces méthodologies a aussi été réalisée.

Conclusions et importance clinique – De façon semblable à la dermatite atopique canine, le FASS est un diagnostic clinique basé sur la présence compatible avec les signes cliniques et l’exclusion d’autres maladies ayant des critères cliniques semblables. L’élimination ou l’exclusion des puces/de l’allergie aux puces, d’autres parasites, des infections et de l’allergie alimentaire est nécessaire avant d’établir un diagnostic de FASS.

Resumen
Introducción – el síndrome atópico felino (FASS) describe un espectro de trastornos de hiper sensibilidad caracterizados por presentaciones clínicas muy diversas que incluyen la piel, los sistemas gastrointestinal y respiratorio. Entre estos trastornos se encuentra el síndrome de piel atópica felina (FASS), en el que la hiper sensibilidad se asocia típicamente con alérgenos ambientales, aunque la alergia alimentaria puede coexistir. También puede producirse la afectación de otros sistemas orgánicos (por ejemplo asma). Debido a su presentación clínica altamente heterogénea, el diagnóstico de FASS puede ser difícil.

Objetivos – Se encomendó a un subgrupo del Comité Internacional sobre Enfermedades Alérgicas de los Animales (ICADA) que resumiera la información más actual sobre las presentaciones clínicas de FASS y que desarrollara pautas de diagnóstico recomendadas.

Métodos – Se realizaron búsquedas en la red de bases de datos de referencias y resúmenes de reuniones internacionales relacionadas con alergias felines. Estos se combinaron con la opinión de expertos cuando fue necesario.

Resultados – Se identificaron un total de 107 publicaciones relevantes para esta revisión. La recopilación de estos datos permitió el desarrollo de una descripción detallada de las características clínicas de FASS y que desarrollara pautas de diagnóstico recomendadas.

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology, 32, 43–e8.
Feline atopic syndrome: treatment

el desarrollo de pautas centradas en la eliminación sistemática de otras afecciones de la piel con características clínicas similares. Dado que los dermatólogos utilizan con frecuencia las pruebas de alergia para respaldar un diagnóstico clínico de FASS, también se realizó una breve revisión de estas metodologías.

**Conclusiones e importancia clínica** – De manera similar a la dermatitis atópica en perros, FASS es un diagnóstico clínico basado en la presencia de signos clínicos compatibles y la exclusión de otras enfermedades con características clínicas similares. La eliminación o exclusión de pulgas/alergia a pulgas, otros parásitos, infecciones y alergia alimentaria es necesaria antes de llegar a un diagnóstico de FASS.

**Zusammenfassung**


**Ziele** – Eine Untergruppe des International Committee on Allergic Diseases of Animals (ICADA) sollte die gängigste Information über die klinischen Präsentationen vom FASS zusammenfassen und diagnostische Richtlinien entwerfen.


**Ergebnisse** – Es wurden insgesamt 107 Publikationen, die für dieses Thema relevant waren, identifiziert. Eine Erfassung dieser Daten erlaubte die Entwicklung einer detaillierten Beschreibung der klinischen Merkmale des FASS und die Entwicklung von Richtlinien, die sich auf die systematische Eliminierung von anderen Hauterkrankungen mit ähnlichen klinischen Charakteristika konzentrieren. Da Allergietests von Dermatologen häufig verwendet werden, um eine klinische Diagnose des FASS zu untermauern, wurde eine kurze Review dieser Methoden durchgeführt.

**Schlussfolgerungen und klinische Bedeutung** – In einer ähnlichen Weise wie bei der atopischen Dermatitis der Hunde, ist das FASS eine klinische Diagnose, die auf dem Vorkommen von kompatiblen klinischen Zeichen und einem Ausschluss anderer Krankheiten mit ähnlichen klinischen Merkmalen beruht. Eine Eliminierung von Flöhen/Flohspeichelallergie, anderer Parasiten, Infektionen und Futterallergie sind zwingend notwendig, bevor die Diagnose einer FASS getroffen werden kann.

**要約**

背景 - ネコアトピー症候群 (FASS) は、皮膚、胃腸、呼吸器系を含む非常に多様な臨床症状を特徴とする一連の過敏症を説明している。これらの障害の中には、食物アレルギーが共存する可能性があるものの、過敏症が通常環境アレルゲンと関連しているネコアトピー性皮膚症候群 (FASS) がある。この臓器系（喘息など）の関与も発症する可能性がある。その非常に不均一な臨床症状のために、FASSの診断は困難な場合もある。

目的 - 動物のアレルギー性疾患に関する国際委員会 (ICADA) のサブグループは、FASSの臨床症状に関する最新情報を要約し、診断ガイドラインを作成する任務を負った。

方法 - オンライン引用データベースと国際会議の要約を検索して、猫アレルギーに関連する出版物を探した。これらは、必要に応じて専門家の意見と組み合わせられた。

結果 - このレビューに関する合計107の出版物が特定された。これらのデータの編集により、FASSの臨床的特徴の詳細な評価の開発および、同様の臨床的特徴を持つ他の皮膚状態の体系的な排除に焦点を当てたガイドラインの開発が可能になった。アレルギー検査はFASSの臨床診断をサポートするために皮膚科医によって頻繁に使用されるため、これらの方法論の簡単なレビューも行われた。

結論と臨床の重要性 - 大アトピー性皮膚炎と同様に、FASSは、互換性のある臨床徵候の存在と、同様の臨床的特徴を持つ他の疾患の除外に基づく臨床診断である。FASSの診断に達する前に、ノミノミアレルギー、他の寄生虫、感染症、および食物アレルギーの排除または排除が義務付けられている。

**提要**

背景 - 猫特異性综合征（FASS）涵盖了一系列过敏性反应疾病，以高度多样化的临床表现为特征，包括皮肤、胃肠和呼吸系统。这些疾病包括猫特异性皮肤综合征（FASS），其中过敏反应通常与环境过敏原相关。尽管食物过敏可能同时存在，也可能累及其他器官系统（如呼吸）。由于其高度异质性的临床表现，FASS的诊断可能具有挑战性。

目的 - 国际动物过敏性疾病委员会 (ICADA) 的一个亚组的任务是总结FASS临床表现的最新信息，并制定诊断指南。

方法 - 检索了107篇关于过敏反应的相关出版物。这些资料能够制定FASS临床特征的详细描述和制定指南，重点是系统性消除具有相似临床特征的其他皮肤疾病，由于皮肤科医生经常使用过敏试验来支持FASS的临床诊断，因此对这些方法进行了简要综述。

© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary Dermatology and the American College of Veterinary Dermatology, 32, 43–e8.
结论和临床重要性 — 与犬特应性皮炎相似，FASS的临床诊断是基于相符的临床症状，并排除具有相似临床特征的其他疾病。在确诊FASS之前，必须消除或排除跳蚤/跳蚤过敏，其他寄生虫，感染和食物过敏。

Resumo
Contexto — A síndrome atópica felina (SAF) descreve um espectro de distúrbios de hipersensibilidade caracterizados por uma apresentação clínica altamente diversa, incluindo a pele, sistema gastrointestinal e respiratório. Dentre esses distúrbios está a síndrome atópica cutânea felina (FASS, feline atopic skin syndrome), na qual hipersensibilidade é tipicamente associada a alérgenos ambientais, apesar de alimentos poderem coexistir. O envolvimento de outros sistemas (ex: asma) pode também ocorrer. Devido a essa apresentação clínica altamente heterogênea, o diagnóstico da FASS pode ser desafiador.
Objetivos — Um subgrupo do International Committee on Allergic Diseases of Animals (ICADA) foi designado a sintetizar as informações mais recentes sobre as apresentações clínicas da FASS, e a desenvolver diretrizes diagnósticas.
Métodos — Bancos de dados de citações online e resumos de congressos internacionais foram utilizados para buscar publicações relacionadas a alergias em felinos. Quando necessário, estes foram combinados com as opiniões dos experts.
Resultados — Um total de 107 publicações relevantes a essa revisão foram identificados. A compilação desses dados permitiu o desenvolvimento de uma descrição detalhada das características clínicas da FASS e o desenvolvimento de diretrizes focando a eliminação sistemática de outras dermatopatias com características similares. Como os testes alérgicos são frequentemente utilizados por dermatologistas para apoiar o diagnóstico clínico de FASS, uma rápida revisão destas metodologias foi realizada.
Conclusões e importância clínica — Semelhante à dermatite atópica em cães, a FASS é um diagnóstico clínico baseado nos sinais clínicos compatíveis e exclusão de outras doenças com características clínicas similares. A eliminação de pulgas/alergia à picada de pulgas, outros parasitas, infeccões e alergia alimentar é mandatória antes de se fechar o diagnóstico da FASS.